Kiniksa Pharmaceuticals (KNSA)
(Delayed Data from NSDQ)
$25.44 USD
-0.28 (-1.09%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $25.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Brokerage Reports
Kiniksa Pharmaceuticals, Ltd. [KNSA]
Reports for Purchase
Showing records 101 - 112 ( 112 total )
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
3Q18; Rilonacept Recurrent Pericarditis Data, Ph 3 Initiation Later this Year
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Unclassified
KPL-716 Demonstrates Meaningful Reductions in Pruritus, Supports PN
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Unclassified
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Unclassified
EADV Data Preview: Looking for Efficacy Signals for KPL-716 in Itch
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Unclassified
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Unclassified
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Unclassified
2Q18 Financials; Pivotal Rilonacept Trial Set to Initiate This Year
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Unclassified
Initiating at OP; Reimagining Opportunities for Rare Inflammatory Diseases
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.